Nanne K.H. de Boer

Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial

Cyriel Y. Ponsioen, E. Joline de Groof, Emma J. Eshuis et al. · ˜The œLancet. Gastroenterology & hepatology · 2017 · 334 citations

Terminal Ileitis, Gastroenterology, Multicentre Trial +4

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial

Bruce E. Sands, Peter M. Irving, Timothy Hoops et al. · The Lancet · 2022 · 277 citations

Immunology, Clinical Trials, Gastroenterology +7

Thiopurine therapy in inflammatory bowel disease patients: Analyses of two 8-year intercept cohorts

Bindia Jharap, Margien L. Seinen, Nanne K.H. de Boer et al. · Inflammatory Bowel Diseases · 2010 · 197 citations · Full text

Ustekinumab for Crohn’s Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study

Vince Biemans, Andrea E. van der Meulen‐de Jong, C. Janneke van der Woude et al. · Journal of Crohn s and Colitis · 2019 · 176 citations · Full text

Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial

Toer Stevens, Maria L. Haasnoot, Geert D’Haens et al. · ˜The œLancet. Gastroenterology & hepatology · 2020 · 173 citations

Terminal Ileitis, Medicine, C Trial +5